
Conference Coverage
Latest Content

Psychiatric Pharmacogenomics: An Overview

Phase 2 Analysis of ML-004 for Autism Spectrum Disorder Fails to Meet Endpoint

FDA Issues CRL for Cytisinicline for Smoking Cessation in Adults

Positive Topline Results From Phase 3 Emerge Study of DT120 ODT in Major Depressive Disorder

Evidence-Based Nonpharmacological Interventions in Schizophrenia: Focus on Cognitive Impairment

Shorts










Digital Edition
Podcasts
Continuing Medical Education
All News

Experts reveal why psych medication nonadherence is common, how to discuss it without blame, and tools like CAE and injectables to prevent relapse.

Key steps for first-episode psychosis: team-based care, low-dose meds, relapse planning, family support, and cannabis harm reduction.

Midlife sleep trouble predicts poorer well-being 9 years later, especially for women. Here's why clinicians should ask about sleep and menopause triggers.

Learn a multidimensional approach to suicide prevention in schizophrenia—screening, insight paradox, cannabis, cognition, trauma, and ethical AI monitoring.

Teens’ pre-bed smartphone scrolling drives more late-night phone use, disrupting sleep and potentially worsening mental health—experts urge bedtime screen limits and device-free bedrooms.

Meta-analysis finds intranasal esketamine boosts remission in MDD and TRD fast, but side effects and short trials leave long-term questions.

Once-nightly regular-release lithium cuts kidney risk, maintains bipolar control, improves adherence, and guides safer serum levels.

Experts unpack why most psychiatric care relies on off‑label meds, how neuroscience guides safe polypharmacy, and what could reshape FDA approvals.

In this inaugural episode, experts discuss the limitations of current diagnosis-based frameworks in suicide research, emphasizing the need for more targeted interventions.

Why psychiatrists must talk about sex: sexual dysfunction can exacerbate comorbid psychiatric disorders and contribute to medication nonadherence.

AbbVie’s short-acting psychedelic bretisilocin shows rapid MADRS drops in phase 2a MDD trials, hinting at scalable, supervised depression care.

Explore the brain’s 5 monoamines—beyond serotonin and dopamine—revealing histamine, melatonin, and trace amines shaping sleep, appetite, and mood.

Explore 2026’s fast-moving psych med pipeline: new Alzheimer agitation option, potential novel ADHD therapy, and promising psilocybin for depression.

Lawsuits, research, and clinicians clash over youth screen addiction—learn more about how problematic social platform use evades diagnosis and how we can curb harm.

Experts urge early bipolar disorder treatment, highlighting lithium’s underuse despite neuroprotective, antisuicidal benefits and evidence that delays worsen outcomes and responsiveness.






























